secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2026-09-03T01:37:16+00:00
Accession:  0001140361-26-035515
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio amends Remix merger to two-step structure; $70M financing via pre-funded warrants
--------------------------------------------------------------------------------

- Amended merger agreement dated Sept 2, 2026 restructures deal into two-step merger (First Merger then Second Merger) to qualify as tax-free reorganization.
- Concurrent financing of ~$70.0M via Remix shares and/or pre-funded warrants at $1.3861/share and $1.3860/warrant.
- Registration rights extended to shares issuable upon pre-funded warrants; resale registration statement to be filed within 30 days post-closing.
- Boards of both companies approved and recommend the transaction; outside date remains Dec 24, 2026.
- No change to economic terms, equity value, or termination fees from original June 24, 2026 agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000114036126035515/0001140361-26-035515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000114036126035515/ef20081513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer